AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Refractory Systemic Lupus Erythematosus

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases NCT06978647Phase 11 site📍 Beijing China Immunotech (Beijing) Biotechnology Co., Ltd. · Tests: YTS109 cell Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease NCT06497387EARLY Phase 11 site📍 Wuhan Tongji Hospital · Tests: PRG-1801 BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases NCT06794008Phase 21 site📍 Beijing Peking University People's Hospital · Tests: BCMA-CD19 CAR-T therapy A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases NCT06980597Phase 12 sites📍 Beijing📍 Beijing Beijing GoBroad Hospital · Tests: OL-108 CD19 CAR-T Therapy for Refractory Childhood-Onset Systemic Lupus Erythematosus NCT07855302Phase 11 site📍 Seoul Seoul National University Hospital · Tests: SNUH-CD19-CAR-T Cells, Lymphodepleting Chemotherapy CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases NCT06941129Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: UCAR T-cell Safety Study of CC312 in Autoimmune Disease Patients NCT06888960EARLY Phase 11 site📍 Tianjin CytoCares Inc · Tests: CC312 Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus NCT06585514Phase 1, Phase 21 site📍 Beijing Beijing GoBroad Hospital · Tests: CD19 CAR-T cells A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus NCT07339332EARLY Phase 11 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: CAR-T Therapy Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus NCT06691152Phase 11 site📍 Hangzhou The Children's Hospital of Zhejiang University School of Me… · Tests: CD19 Universal CAR-T cells A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases NCT07104721Phase 11 site📍 Hefei China Immunotech (Beijing) Biotechnology Co., Ltd. · Tests: YTS109 cell Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE NCT07031713Phase 11 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: CAR-T Therapy Immune Profiling of Refractory cSLE Exposed to CD3×CD19 BiTE NCT07352332n/a1 site📍 Hangzhou The Children's Hospital of Zhejiang University School of Me… Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases NCT07301164EARLY Phase 11 site📍 Beijing Peking University Third Hospital · Tests: BCT301 Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE NCT07233642Phase 11 site📍 Hangzhou The Children's Hospital of Zhejiang University School of Me… · Tests: CD19 CAR-T cells Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases NCT07121777NA1 site📍 Hefei Anhui Provincial Hospital · Tests: Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis Study of CD19 CAR-T Therapy for Refractory SLE NCT07403097Phase 11 site📍 Chongqing Chongqing Precision Biotech Co., Ltd · Tests: PTOC1 An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases NCT07174843EARLY Phase 11 site📍 Shanghai Shanghai Cell Therapy Group Co.,Ltd · Tests: CD19/CD22/BCMA CAR-T cells(BZE2204) Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease NCT06497361EARLY Phase 11 site📍 Wuhan Tongji Hospital · Tests: PRG-2311 A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases NCT07413341Phase 11 site📍 Shanghai Therorna · Tests: TI-0032-III injection IASO207 Injection for Active Refractory Systemic Lupus Erythematosus (SLE) NCT07617740EARLY Phase 11 site📍 Beijing Peking University People's Hospital · Tests: IASO207 Injection Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases NCT07085676Phase 11 site📍 Jerusalem Polina Stepensky · Tests: HBI0101 CART A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus NCT07444307Phase 13 sites📍 Hefei📍 Wuhan📍 Beijing Hangzhou Qihan Biotech Co., Ltd. · Tests: QT-019B Cell Injection Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus NCT06946485EARLY Phase 11 site📍 Nanjing The Affiliated Nanjing Drum Tower Hospital of Nanjing Unive… · Tests: Universal anti-CD70 CAR-T (CHT101) Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases NCT06428188Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: BCMA/CD19 CAR-T cells UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis NCT07109986Phase 11 site📍 Nanjing Nanjing IASO Biotechnology Co., Ltd. · Tests: UB-VV410 Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children NCT06904729Phase 31 site📍 Guangzhou Guangzhou Women and Children's Medical Center · Tests: Low-dose CAR-T cells group, High-dose CAR-T cells group Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases NCT06614270NA1 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Anti-CD19 IL-10/IL15 CAR-NK CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH NCT06947460Phase 1, Phase 21 site📍 Beijing Beijing GoBroad Hospital · Tests: CD19-BCMA CAR-T cells infusion An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease NCT06379646NA1 site📍 Shanghai China Immunotech (Beijing) Biotechnology Co., Ltd. · Tests: YTS109
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy